跳至主要内容
临床试验/NCT04113941
NCT04113941Unknown3 期

A Randomized, Double-Blind, Placebo-controlled, Multi-center, Phase 3 Study to Evaluate the Efficacy and Safety of MEDITOXIN® in Subject With Idiopathic Overactive Bladder

Medy-Tox1 个研究点 分布在 1 个国家目标入组 216 人开始时间: 2019年8月23日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
发起方
入组人数
216
试验地点
1
主要终点
The change in the daily average UI (Urinary Incontinence) episodes

研究概览

简要总结

This study is for patients who have idiopathic overactive bladder symptoms. This study will evaluate efficacy and safety of Neuronox® against placebo.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
20 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male and female subjects aged above 20
  • Patient with overactive bladder symptoms lasting at least 6 months

排除标准

  • Patient with a history of surgery or a disease that may affect bladder function.

研究组 & 干预措施

Neuronox®

Experimental

Neuronox® total 100U, inject 5U/0.5mL per site, 20 sites

干预措施: Neuronox (Drug)

Placebo

Placebo Comparator

Normal saline, same volume with Experimental arm

干预措施: Placebo (Drug)

结局指标

主要结局

The change in the daily average UI (Urinary Incontinence) episodes

时间窗: 12 weeks

次要结局

未报告次要终点

研究者

发起方
Medy-Tox
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验